Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
Open accessThe DOI matches its Crossref record; 94 of the 96 references it cites were found in a registry or an index.
Abstract
Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved proteasome inhibitors (bortezomib and carlfilzomib), as well as newer agents under development. Emphasis is placed on the clinical use of proteasome inhibitors, including management of side effects and combination with other agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second-generation carfilzomib is irreversible and more specifically inhibits chymotrypsin-like activity than bortezomib, the reversible first-generation inhibitor, which also inhibits lysosomal and calcium-activated cellular proteases (54, 83).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“bortezomib use in humans was associated with peripheral neuropathy, thrombocytopenia, and neutropenia (70).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [70]
In the citing paper
“Proteasome inhibitors (PIs) are licensed for multiple myeloma.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [54]
In the citing paper
“Although no toxicity was found in the animal models, peripheral neuropathy and myelosuppression are adverse effects observed in humans (54).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T., Chang, J., Markman, M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“Phase 2 studies demonstrating the effectiveness of this agent in relapsed/refractory MM were reported 11 years ago [30].”
BackgroundImproved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,673
Kumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2014) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,369
The proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Obeng, E. A., Carlson, L. M., Gutman, D. M., Harrington, W. J., Lee, K. P., & Boise, L. H. (2006) · Blood · doi:10.1182/blood-2005-08-3531 · Cited by 1,143
Research works printed but not linked: 1
- Kaufman J.L. Siegal D. Haematologica. Clinical Profile of Once-Daily, Modified-Release Oprozomib Tablets in Patients with Hematologic Malignancies: Results of a Phase 1b/2 Trial Proceedings of Onyx Pharmaceuticals Announces Data Presentations at the 18th Congress of the European Hematology Association South San Francisco, CA, USA 21 May 2013
Cited by
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Spencer, A., Lentzsch, S., Weisel, K., Avet-Loiseau, H., Mark, T. M., Spicka, I., Masszi, T., Lauri, B., Levin, M.-D., Bosi, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.194118 · Cited by 263
Discovery and characterization of highly potent and selective allosteric USP7 inhibitors
Gavory, G., O'Dowd, C. R., Helm, M. D., Flasz, J., Arkoudis, E., Dossang, A., Hughes, C., Cassidy, E., McClelland, K., Odrzywol, E., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2528 · Cited by 224
Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
Serrano-del Valle, A., Anel, A., Naval, J., & Marzo, I. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00050 · Cited by 198
Multiple myeloma in the marrow: pathogenesis and treatments
Fairfield, H., Falank, C., Avery, L., & Reagan, M. R. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13038 · Cited by 183
Mateos, M.-V., Sonneveld, P., Hungria, V., Nooka, A. K., Estell, J. A., Barreto, W., Corradini, P., Min, C.-K., Medvedova, E., Weisel, K., et al. (2020) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2019.09.623 · Cited by 160
The ubiquitin–proteasome system in kidney physiology and disease
Meyer-Schwesinger, C. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0148-1 · Cited by 159
Regulation of Protein Degradation by Proteasomes in Cancer
Jang, H. H. (2018) · Journal of Cancer Prevention · doi:10.15430/jcp.2018.23.4.153 · Cited by 113
Li, X., Kong, L., Yang, Q., Duan, A., Ju, X., Cai, B., Chen, L., An, T., & Li, Y. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011396 · Cited by 97
Ettari, R., Zappalà, M., Grasso, S., Musolino, C., Innao, V., & Allegra, A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.09.001 · Cited by 96
Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors
Gao, Y., Tai, W., Wang, N., Li, X. O., Jiang, S., Debnath, A. K., Du, L., & Chen, S. (2019) · Viruses · doi:10.3390/v11111019 · Cited by 82
Rastgoo, N., Pourabdollah, M., Abdi, J., Reece, D. E., & Chang, H. (2018) · Leukemia · doi:10.1038/s41375-018-0140-y · Cited by 79
Cellular Responses to Proteasome Inhibition: Molecular Mechanisms and Beyond
Albornoz, N., Bustamante, H. A., Soza, A., & Burgos, P. V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143379 · Cited by 80
A One Health approach to overcoming fungal disease and antifungal resistance
Woods, M., McAlister, J. A., & Geddes‐McAlister, J. (2023) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1610 · Cited by 80
Geddes, J. M. H., Caza, M., Croll, D., Stoynov, N., Foster, L. J., & Kronstad, J. W. (2016) · mBio · doi:10.1128/mbio.01862-15 · Cited by 67
Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
“Although no toxicity was found in the animal models, peripheral neuropathy and myelosuppression are adverse effects observed in humans (54).”
BackgroundA versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
Bonomi, A., Steimberg, N., Benetti, A., Berenzi, A., Alessandri, G., Pascucci, L., Boniotti, J., Coccè, V., Sordi, V., Pessina, A., et al. (2016) · Hematological Oncology · doi:10.1002/hon.2306 · Cited by 51
The effects of proteasome inhibitors on bone remodeling in multiple myeloma
Zangari, M., & Suva, L. J. (2016) · Bone · doi:10.1016/j.bone.2016.02.019 · Cited by 46
Proteasome‐mediated proteostasis: Novel medicinal and pharmacological strategies for diseases
Mishra, R., Upadhyay, A., Prajapati, V. K., & Mishra, A. (2018) · Medicinal Research Reviews · doi:10.1002/med.21502 · Cited by 51
Raje, N. S., Moreau, P., Terpos, E., Benboubker, L., Grząśko, N., Holstein, S. A., Oriol, A., Huang, S., Beksaç, M., Kuliczkowski, K., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14483 · Cited by 48
Li, T., Timmins, H. C., King, T., Kiernan, M. C., Goldstein, D., & Park, S. B. (2019) · Hematological Oncology · doi:10.1002/hon.2706 · Cited by 48
NFκB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG
Caulfield, M. E., Guo, Y. X., Johnson, R. K., McCarthy, C. B., Fitz‐Gibbon, P. D., Lucchinetti, C. F., & Howe, C. L. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0403-8 · Cited by 41
From Naturally-Sourced Protease Inhibitors to New Treatments for Fungal Infections
Gutierrez‐Gongora, D., & Geddes‐McAlister, J. (2021) · Journal of Fungi · doi:10.3390/jof7121016 · Cited by 40
Al-Shammari, A. M., Rameez, H., & Altaee, M. F. (2016) · Oncolytic Virotherapy · doi:10.2147/ov.s95250 · Cited by 41
The Functional and Mechanistic Roles of Immunoproteasome Subunits in Cancer
Tripathi, S. C., Vedpathak, D., & Ostrin, E. J. (2021) · Cells · doi:10.3390/cells10123587 · Cited by 45
Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview
Guedes, R. A., Serra, P., Salvador, J. A. R., & Guedes, R. C. (2016) · Molecules · doi:10.3390/molecules21070927 · Cited by 33
Photocontrolled activation of small molecule cancer therapeutics
Dcona, M. M., Mitra, K., & Hartman, M. C. T. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00107d · Cited by 36
Cardaci, T. D., Machek, S. B., Wilburn, D. T., Hwang, P. S., & Willoughby, D. S. (2020) · Journal of the American College of Nutrition · doi:10.1080/07315724.2020.1783721 · Cited by 35
Evaluation of pretreatment red cell distribution width in patients with multiple myeloma
Wang, J., Xie, X., Cheng, F., Xin Min, Z. H. O. U., Xia, J., Qian, X., Wang, L., & Guo, H. (2017) · Cancer Biomarkers · doi:10.3233/cbm-170032 · Cited by 30
Salimi, A., Schroeder, K. M., Schemionek, M., Vieri, M., Maletzke, S., Gezer, D., Masouleh, B. K., & Appelmann, I. (2022) · BMC Cancer · doi:10.1186/s12885-022-09775-y · Cited by 31
Ixazomib: a novel drug for multiple myeloma
Zanwar, S., Abeykoon, J. P., & Kapoor, P. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1518129 · Cited by 30
Discovery of an OTUD3 inhibitor for the treatment of non-small cell lung cancer
Zhang, Y., Du, T., Liu, N., Wang, J., Zhang, L., Cui, C., Li, C., Zhang, X., Wu, B., Zhang, J., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05900-2 · Cited by 26
Immunoproteasome Function in Normal and Malignant Hematopoiesis
Santamaría, N. T., Ebstein, F., Heidel, F. H., & Krüger, E. (2021) · Cells · doi:10.3390/cells10071577 · Cited by 31
Jolles, S. R. A., Giralt, S., Kerre, T. C. C., Lazarus, H. M., Mustafa, S. S., Ria, R., & Vinh, D. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1098326 · Cited by 28
Ren, Y., Li, X., Wang, W., He, W., Wang, J., & Wang, Y. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.05.010 · Cited by 23
In vitro assessment of chemotherapy-induced neuronal toxicity
Snyder, C. A., Yu, L., Ngo, T., Sheinson, D. M., Zhu, Y., Tseng, M., Misner, D., & Staflin, K. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.02.004 · Cited by 22
Advancements, challenges, and future frontiers in covalent inhibitors and covalent drugs: A review
Hameed, M. S., Cao, H., Guo, L., Zeng, L., & Ren, Y. (2024) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2024.100217 · Cited by 32
APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome
Palumbo, R., Gogliettino, M., Cocca, E., Iannitti, R., Sandomenico, A., Ruvo, M., Balestrieri, M., Rossi, M., & Palmieri, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101614 · Cited by 21
Gutierrez‐Gongora, D., Raouf-Alkadhimi, F., Prosser, R. S., & Geddes‐McAlister, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-32140-3 · Cited by 20
Impaired proteostasis in rare neurological diseases
Osinalde, N., Duarri, A., Ramírez, J., Barrio, R., de Nanclares, G. P., & Mayor, U. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.10.007 · Cited by 19
Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
Bennett, M. K., Li, M., Tea, M. N., Pitman, M. R., Toubia, J., Wang, P. P.-S., Anderson, D., Creek, D. J., Orlowski, R. Z., Gliddon, B. L., et al. (2021) · Neoplasia · doi:10.1016/j.neo.2021.11.009 · Cited by 19
Redic, K. A., Hough, S. M., & Price, E. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s87962 · Cited by 19
Hari, P., Paba‐Prada, C. E., Voorhees, P. M., Frye, J. W., Chang, Y., Moreau, P., Zonder, J. A., Boccia, R. V., & Shain, K. H. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.106172 · Cited by 18
RPE Cells Engulf Microvesicles Secreted by Degenerating Rod Photoreceptors
Ropelewski, P., & Imanishi, Y. (2020) · eNeuro · doi:10.1523/eneuro.0507-19.2020 · Cited by 17
Guillen, V. S., Ziegler, Y., Gopinath, C., Kumar, S., Dey, P., Plotner, B. N., Dawson, N. Z., Kim, S. H., Katzenellenbogen, J. A., & Katzenellenbogen, B. S. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06878-3 · Cited by 15
The proteasome modulates endocytosis specifically in glomerular cells to promote kidney filtration
Sachs, W., Blume, L., Loreth, D., Schebsdat, L., Hatje, F. A., Koehler, S., Wedekind, U., Sachs, M., Zieliniski, S., Brand, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46273-0 · Cited by 13
Nonselective proteasome inhibitors in multiple myeloma and future perspectives
Gavriatopoulou, M., Malandrakis, P., Ntanasis‐Stathopoulos, I., & Dimopoulos, M. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999411 · Cited by 14
Leleu, X. P., Kyriakou, C. A., Broek, I. V., Murphy, P. T., Bacon, P., Lewis, P., Gilet, H., Arnould, B., & Petrucci, M. T. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.20 · Cited by 12
Amita, M., Takahashi, T., Igarashi, H., & Nagase, S. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.03.029 · Cited by 12
Advances in pharmacotherapy to treat kidney transplant rejection
Bamoulid, J., Staeck, O., Halleck, F., Dürr, M., Paliege, A., Lachmann, N., Brakemeier, S., Liefeldt, L., & Budde, K. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1056734 · Cited by 15
El‐Mesery, M., Anany, M. A., Hazem, S. H., & Shaker, M. E. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108513 · Cited by 12
Total synthesis and absolute stereochemistry of the proteasome inhibitors cystargolides A and B
Tello‐Aburto, R., Hallada, L. P., Niroula, D., & Rogelj, S. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob01821h · Cited by 11
Carfilzomib for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma
Stewart, A. K. (2015) · Future Oncology · doi:10.2217/fon.15.123 · Cited by 11
An Update on the Role of Ubiquitination in Melanoma Development and Therapies
Soysouvanh, F., Giuliano, S., Habel, N., Hachem, N. E., Pisibon, C., Bertolotto, C., & Ballotti, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051133 · Cited by 11
A new era in cancer therapy: targeting the Proteasome-Bcl-2 axis
Soni, S., Anang, V., Zhao, Y., Horowitz, J. C., Nho, R. S., & Mebratu, Y. A. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03505-5 · Cited by 10
Rinaldi, R., Miglionico, R., Nigro, I., D’Orsi, R., Chiummiento, L., Funicello, M., Lupattelli, P., Laurenzana, I., Sgambato, A., Monné, M., et al. (2021) · Cells · doi:10.3390/cells10113052 · Cited by 9
Wójcik-Mieszawska, S., Lewtak, K., Skwarek, E., Dębowski, D., Gitlin‐Domagalska, A., Nowak, J., Wydrych, J., Pawelec, J., & Fiołka, M. J. (2023) · Scientific Reports · doi:10.1038/s41598-023-41281-4 · Cited by 7
Eleftheriadis, T., Pissas, G., Antoniadi, G., Liakopoulos, V., & Stefanidis, I. (2016) · International Urology and Nephrology · doi:10.1007/s11255-016-1247-6 · Cited by 6
Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors
Nan, G., Huang, L. H., Li, Y., Yang, Y., Yang, Y., Li, K., Lai, F., Chen, X., & Xiao, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114252 · Cited by 6
Reversible mislocalization of a disease-associated MRE11 splice variant product
Hartlerode, A. J., Regal, J. A., & Ferguson, D. O. (2018) · Scientific Reports · doi:10.1038/s41598-018-28370-5 · Cited by 8
Nagai, Y., Mimura, N., Rizq, O., Isshiki, Y., Oshima, M., Rizk, M., Saraya, A., Koide, S., Nakajima‐Takagi, Y., Miyota, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81577-x · Cited by 7
Lignet, F., Becker, A. D., Gimmi, C. D., Rohdich, F., & Bawab, S. E. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12743 · Cited by 5
Gao, Y., Zhou, D., Bai, X. F., Wang, Y., Wang, C., & Bi, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1570017 · Cited by 7
Review of Patents for Anticancer Agents Targeting Adenosine Monophosphate-Activated Protein Kinase
Choi, H., Park, S., Lee, J., & Hwang, J. (2023) · Journal of Medicinal Food · doi:10.1089/jmf.2023.k.0026 · Cited by 4
Ghasemi, M., Alpsoy, S., Türk, S., Malkan, Ü. Y., Atakan, Ş., Haznedaroğlu, İ. C., Güneş, G., Gündüz, M., Yılmaz, B., Etgül, S., et al. (2016) · Turkish Journal of Hematology · doi:10.4274/tjh.2015.0145 · Cited by 4
Mohammed, J. A., Akomolafe, T., Aljurf, M. D., Savani, B. N., & Hashmi, S. K. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0095-7 · Cited by 5
Decoding the secrets: how conformational and structural regulators inhibit the human 20S proteasome
Fernandes, P. M. P., Guedes, R. A., Victor, B. L., Salvador, J. A. R., & Guedes, R. C. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1322628 · Cited by 4
Bennett, M. K., Pitson, S. M., & Wallington-Beddoe, C. T. (2021) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-73440-4_4 · Cited by 2
Multiple myeloma inhibitory effects of natural compounds: enhancement through nanoparticle carriers
Wong, E. C., Staskiewicz, A., Pruner, J., Lee, J. Y. H., Tucker, M., Smith, B., Rogers, L. J., Asuni, G., & Wang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1589090 · Cited by 2
Bera, P., Singh, M. R., Singh, D., & Keshavkant, S. (2025) · BioNanoScience · doi:10.1007/s12668-025-02092-1 · Cited by 2
Pandya, S., Pandya, A., Larsen, A., & Gowin, K. L. (2023) · Integrative Cancer Therapies · doi:10.1177/15347354231159322 · Cited by 2
Li, Y., Nan, G., Hou, X., Yang, Y., Yang, Y., Yang, Y., Li, K., & Xiao, Z. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115856 · Cited by 2
Structural mechanism of 26S proteasome regulation and its pharmacological modulation
Pei, K., Zhao, L., Hu, J., & Mao, Y. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113256 · Cited by 2
Practical recommendations for infectious prophylaxis and vaccination in multiple myeloma patients
Bergantim, R., Roque, A. I., Jorge, A., Freitas, J. G., Miranda, M. T., Nunes, M., Ionita, A., Bernardo, P. V., Vieira, J., Aguiar, E. V., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1847793 · Cited by 1
Myeloma; living better and living longer - a look at the advances
Grammatico, S., Vozella, F., Scalzulli, E., Angelis, G. D., & Petrucci, M. T. (2017) · Expert Review of Quality of Life in Cancer Care · doi:10.1080/23809000.2017.1337469
Nursing support during treatment of multiple myeloma with proteasome inhibitors
Aerts, E., Szabó, Z. R., & Hellberg-Naegele, M. (2018) · Cancer Nursing Practice · doi:10.7748/cnp.2018.e1488
Characterising the Biological Activity of a Trichlorovinyl Cysteine-Containing Mycothiol Analogue
Harmos, P. (2018) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17069144.v1
Altundağ, E. M., Yılmaz, A. M., Şahin, A., & Karademir-Yilmaz, B. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220329175501
Liu, X., Doherty, L. M., Felix, A., & Buhrlage, S. J. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch7
Miličević, L., Matošević, M., Ivandić, E., Prlić, M. F., Živko, M., Bašić‐Kinda, S., Batinić, J., Bradamante, M., Bulimbašić, S., Jelaković, B., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3047279/v1
Recent Advances in Multiple myeloma
Paikray, E., Rout, A., & Tripathy, R. (2024) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2882
The role of synthetic protease inhibitors in breast cancer
Sirasanagandla, S. R., & Al‐Huseini, I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-30098-1.00034-3
Role of proteasome in the development of chemoresistance in multiple myeloma
Thomas, S. M., Jayakumar, S., & Veerabathiran, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-30098-1.00026-4
A Hybrid Logical-Stochastic Modeling Framework for Signal Transduction: Application to Angiogenesis
de Oliveira, L. R., & Gavoçi, E. (2025) · Communications in computer and information science · doi:10.1007/978-3-032-07370-9_2
NF-κBシグナルを標的とした抗がん剤開発と炎症制御機構に関する研究
UEMATAU, A. (2018) · Institutional Repositories DataBase (IRDB)
Ballouhey, O. (2021) · theses.fr (ABES) · doi:10.70675/c92eabe1z7868z43c0z9df4zf6e02e91d61f
Metadata
- Authors
- Merin, N., & Kelly, K.
- Affiliations
- University of Southern California (US)
- Corresponding author
- Kelly, Kevin
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2014-12-24
- Volume
- 8
- Issue
- 1
- Pages
- 1-20
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC4381198
- OpenAlex
- W1994895013
- Cited by
- 90
- References
- 96
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 6 · 2023: 10 · 2022: 6 · 2021: 12 · 2020: 5 · 2019: 7 · 2018: 12 · 2017: 6 · 2016: 13 · 2015: 5
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- California Institute for Regenerative Medicine
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- multiple myeloma, proteasome inhibitors, bortezomib, carfilzomib, adverse drug reactions, combination therapy, plasma cell neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.